S&P 500   3,855.36
DOW   30,960.00
QQQ   328.11
pixel
S&P 500   3,855.36
DOW   30,960.00
QQQ   328.11
pixel
S&P 500   3,855.36
DOW   30,960.00
QQQ   328.11
pixel
S&P 500   3,855.36
DOW   30,960.00
QQQ   328.11
pixel
Log in
NASDAQ:ARAY

Accuray Competitors

$5.08
-0.03 (-0.59 %)
(As of 01/25/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.95
Now: $5.08
$5.20
50-Day Range
$4.12
MA: $4.60
$5.38
52-Week Range
$1.33
Now: $5.08
$5.40
Volume1.00 million shs
Average Volume992,630 shs
Market Capitalization$463.67 million
P/E Ratio36.29
Dividend YieldN/A
Beta2.06

Competitors

Accuray (NASDAQ:ARAY) Vs. ABT, MDT, SYK, ISRG, BDX, and EW

Should you be buying ARAY stock or one of its competitors? Companies in the sub-industry of "health care equipment" are considered alternatives and competitors to Accuray, including Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), and Edwards Lifesciences (EW).

Accuray (NASDAQ:ARAY) and Abbott Laboratories (NYSE:ABT) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.

Risk & Volatility

Accuray has a beta of 2.06, indicating that its stock price is 106% more volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500.

Profitability

This table compares Accuray and Abbott Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Accuray3.41%4.33%0.56%
Abbott Laboratories10.50%18.19%8.29%

Valuation and Earnings

This table compares Accuray and Abbott Laboratories' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Accuray$382.93 million1.21$3.83 million($0.08)-63.50
Abbott Laboratories$31.90 billion6.37$3.69 billion$3.2435.41

Abbott Laboratories has higher revenue and earnings than Accuray. Accuray is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

69.8% of Accuray shares are owned by institutional investors. Comparatively, 72.6% of Abbott Laboratories shares are owned by institutional investors. 4.0% of Accuray shares are owned by company insiders. Comparatively, 1.7% of Abbott Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for Accuray and Abbott Laboratories, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Accuray01302.75
Abbott Laboratories121302.75

Accuray currently has a consensus price target of $8.00, suggesting a potential upside of 57.48%. Abbott Laboratories has a consensus price target of $115.6875, suggesting a potential upside of 0.84%. Given Accuray's higher possible upside, equities research analysts plainly believe Accuray is more favorable than Abbott Laboratories.

Summary

Abbott Laboratories beats Accuray on 10 of the 13 factors compared between the two stocks.

Accuray (NASDAQ:ARAY) and Medtronic (NYSE:MDT) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, valuation, institutional ownership, earnings and dividends.

Volatility and Risk

Accuray has a beta of 2.06, meaning that its share price is 106% more volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500.

Profitability

This table compares Accuray and Medtronic's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Accuray3.41%4.33%0.56%
Medtronic12.69%9.71%5.30%

Earnings & Valuation

This table compares Accuray and Medtronic's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Accuray$382.93 million1.21$3.83 million($0.08)-63.50
Medtronic$28.91 billion5.44$4.79 billion$4.5925.47

Medtronic has higher revenue and earnings than Accuray. Accuray is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

69.8% of Accuray shares are held by institutional investors. Comparatively, 79.2% of Medtronic shares are held by institutional investors. 4.0% of Accuray shares are held by company insiders. Comparatively, 0.5% of Medtronic shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings for Accuray and Medtronic, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Accuray01302.75
Medtronic032012.92

Accuray presently has a consensus price target of $8.00, indicating a potential upside of 57.48%. Medtronic has a consensus price target of $122.2963, indicating a potential upside of 4.62%. Given Accuray's higher probable upside, research analysts clearly believe Accuray is more favorable than Medtronic.

Summary

Medtronic beats Accuray on 12 of the 15 factors compared between the two stocks.

Accuray (NASDAQ:ARAY) and Stryker (NYSE:SYK) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, valuation, institutional ownership, earnings and dividends.

Volatility and Risk

Accuray has a beta of 2.06, meaning that its share price is 106% more volatile than the S&P 500. Comparatively, Stryker has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500.

Profitability

This table compares Accuray and Stryker's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Accuray3.41%4.33%0.56%
Stryker12.35%20.94%8.77%

Earnings & Valuation

This table compares Accuray and Stryker's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Accuray$382.93 million1.21$3.83 million($0.08)-63.50
Stryker$14.88 billion6.05$2.08 billion$8.2629.00

Stryker has higher revenue and earnings than Accuray. Accuray is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

69.8% of Accuray shares are held by institutional investors. Comparatively, 71.5% of Stryker shares are held by institutional investors. 4.0% of Accuray shares are held by company insiders. Comparatively, 6.8% of Stryker shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings for Accuray and Stryker, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Accuray01302.75
Stryker271412.58

Accuray presently has a consensus price target of $8.00, indicating a potential upside of 57.48%. Stryker has a consensus price target of $227.4783, indicating a potential downside of 5.04%. Given Accuray's stronger consensus rating and higher probable upside, research analysts clearly believe Accuray is more favorable than Stryker.

Summary

Stryker beats Accuray on 12 of the 15 factors compared between the two stocks.

Accuray (NASDAQ:ARAY) and Intuitive Surgical (NASDAQ:ISRG) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, valuation, institutional ownership, earnings and dividends.

Volatility and Risk

Accuray has a beta of 2.06, meaning that its share price is 106% more volatile than the S&P 500. Comparatively, Intuitive Surgical has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500.

Profitability

This table compares Accuray and Intuitive Surgical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Accuray3.41%4.33%0.56%
Intuitive Surgical24.45%12.08%10.44%

Earnings & Valuation

This table compares Accuray and Intuitive Surgical's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Accuray$382.93 million1.21$3.83 million($0.08)-63.50
Intuitive Surgical$4.48 billion19.74$1.38 billion$9.9575.58

Intuitive Surgical has higher revenue and earnings than Accuray. Accuray is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

69.8% of Accuray shares are held by institutional investors. Comparatively, 86.5% of Intuitive Surgical shares are held by institutional investors. 4.0% of Accuray shares are held by company insiders. Comparatively, 1.6% of Intuitive Surgical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings for Accuray and Intuitive Surgical, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Accuray01302.75
Intuitive Surgical381002.33

Accuray presently has a consensus price target of $8.00, indicating a potential upside of 57.48%. Intuitive Surgical has a consensus price target of $736.0588, indicating a potential downside of 2.12%. Given Accuray's stronger consensus rating and higher probable upside, research analysts clearly believe Accuray is more favorable than Intuitive Surgical.

Summary

Intuitive Surgical beats Accuray on 10 of the 14 factors compared between the two stocks.

Accuray (NASDAQ:ARAY) and Becton, Dickinson and (NYSE:BDX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, valuation, institutional ownership, earnings and dividends.

Volatility and Risk

Accuray has a beta of 2.06, meaning that its share price is 106% more volatile than the S&P 500. Comparatively, Becton, Dickinson and has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500.

Profitability

This table compares Accuray and Becton, Dickinson and's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Accuray3.41%4.33%0.56%
Becton, Dickinson and5.11%13.30%5.60%

Earnings & Valuation

This table compares Accuray and Becton, Dickinson and's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Accuray$382.93 million1.21$3.83 million($0.08)-63.50
Becton, Dickinson and$17.12 billion4.42$874 million$10.2025.51

Becton, Dickinson and has higher revenue and earnings than Accuray. Accuray is trading at a lower price-to-earnings ratio than Becton, Dickinson and, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

69.8% of Accuray shares are held by institutional investors. Comparatively, 83.2% of Becton, Dickinson and shares are held by institutional investors. 4.0% of Accuray shares are held by company insiders. Comparatively, 0.8% of Becton, Dickinson and shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings for Accuray and Becton, Dickinson and, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Accuray01302.75
Becton, Dickinson and07702.50

Accuray presently has a consensus price target of $8.00, indicating a potential upside of 57.48%. Becton, Dickinson and has a consensus price target of $279.6667, indicating a potential upside of 7.46%. Given Accuray's stronger consensus rating and higher probable upside, research analysts clearly believe Accuray is more favorable than Becton, Dickinson and.

Summary

Becton, Dickinson and beats Accuray on 10 of the 14 factors compared between the two stocks.

Accuray (NASDAQ:ARAY) and Edwards Lifesciences (NYSE:EW) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, valuation, institutional ownership, earnings and dividends.

Volatility and Risk

Accuray has a beta of 2.06, meaning that its share price is 106% more volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500.

Profitability

This table compares Accuray and Edwards Lifesciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Accuray3.41%4.33%0.56%
Edwards Lifesciences18.18%29.00%18.10%

Earnings & Valuation

This table compares Accuray and Edwards Lifesciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Accuray$382.93 million1.21$3.83 million($0.08)-63.50
Edwards Lifesciences$4.35 billion12.31$1.05 billion$1.8646.18

Edwards Lifesciences has higher revenue and earnings than Accuray. Accuray is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

69.8% of Accuray shares are held by institutional investors. Comparatively, 80.9% of Edwards Lifesciences shares are held by institutional investors. 4.0% of Accuray shares are held by company insiders. Comparatively, 1.5% of Edwards Lifesciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings for Accuray and Edwards Lifesciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Accuray01302.75
Edwards Lifesciences271202.48

Accuray presently has a consensus price target of $8.00, indicating a potential upside of 57.48%. Edwards Lifesciences has a consensus price target of $90.8704, indicating a potential upside of 5.80%. Given Accuray's stronger consensus rating and higher probable upside, research analysts clearly believe Accuray is more favorable than Edwards Lifesciences.

Summary

Edwards Lifesciences beats Accuray on 10 of the 14 factors compared between the two stocks.


Accuray Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Abbott Laboratories logo
ABT
Abbott Laboratories
2.4$114.72-1.6%$203.33 billion$31.90 billion60.70Upcoming Earnings
Medtronic logo
MDT
Medtronic
2.7$116.90-0.3%$157.35 billion$28.91 billion44.62
Stryker logo
SYK
Stryker
2.0$239.55-0.2%$90.02 billion$14.88 billion51.96Upcoming Earnings
Intuitive Surgical logo
ISRG
Intuitive Surgical
1.7$752.01-1.1%$88.40 billion$4.48 billion85.65Earnings Announcement
Becton, Dickinson and logo
BDX
Becton, Dickinson and
2.0$260.24-0.6%$75.69 billion$17.12 billion95.33Dividend Announcement
News Coverage
Edwards Lifesciences logo
EW
Edwards Lifesciences
1.6$85.89-0.4%$53.53 billion$4.35 billion68.71Upcoming Earnings
Boston Scientific logo
BSX
Boston Scientific
2.2$36.78-0.7%$52.67 billion$10.74 billion14.09
IDEXX Laboratories logo
IDXX
IDEXX Laboratories
1.5$489.21-0.7%$41.73 billion$2.41 billion85.23Upcoming Earnings
Baxter International logo
BAX
Baxter International
2.3$80.10-0.7%$40.92 billion$11.36 billion45.51
DexCom logo
DXCM
DexCom
1.9$376.39-1.7%$36.14 billion$1.48 billion155.53Insider Selling
ResMed logo
RMD
ResMed
1.4$221.68-2.8%$32.12 billion$2.96 billion47.57Upcoming Earnings
Hologic logo
HOLX
Hologic
1.9$76.34-0.8%$19.62 billion$3.78 billion18.18Upcoming Earnings
Insulet logo
PODD
Insulet
1.3$288.91-0.5%$19.05 billion$738.20 million656.63
Teleflex logo
TFX
Teleflex
2.0$382.14-1.1%$17.80 billion$2.60 billion49.18
STERIS logo
STE
STERIS
2.1$190.41-0.9%$16.25 billion$3.03 billion38.62Upcoming Earnings
Varian Medical Systems logo
VAR
Varian Medical Systems
1.3$175.33-0.1%$16.02 billion$3.17 billion59.84
Abiomed logo
ABMD
Abiomed
1.5$348.32-0.1%$15.74 billion$840.88 million76.55Upcoming Earnings
Masimo logo
MASI
Masimo
1.4$257.09-2.6%$14.15 billion$937.84 million66.78
Hill-Rom logo
HRC
Hill-Rom
2.0$101.16-1.7%$6.71 billion$2.88 billion30.47
Globus Medical logo
GMED
Globus Medical
1.4$64.44-1.4%$6.36 billion$785.37 million70.04
Integra LifeSciences logo
IART
Integra LifeSciences
1.4$69.36-0.1%$5.85 billion$1.52 billion103.52
NuVasive logo
NUVA
NuVasive
1.5$56.80-0.2%$2.91 billion$1.17 billion-258.18
AtriCure logo
ATRC
AtriCure
1.3$58.30-1.3%$2.62 billion$230.81 million-50.70
Integer logo
ITGR
Integer
2.3$78.15-1.2%$2.57 billion$1.26 billion35.52
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.3$46.51-0.3%$1.87 billion$236.54 million-70.47
Alphatec logo
ATEC
Alphatec
0.8$14.92-0.7%$1.17 billion$113.43 million-13.56
CryoLife logo
CRY
CryoLife
1.5$24.96-1.2%$969.87 million$276.22 million-65.68
Orthofix Medical logo
OFIX
Orthofix Medical
1.2$44.94-2.2%$868.77 million$459.95 million37.45
AngioDynamics logo
ANGO
AngioDynamics
1.6$18.55-1.9%$704.04 million$264.16 million-4.15
Surmodics logo
SRDX
Surmodics
1.5$46.33-1.0%$633.89 million$94.86 million579.13News Coverage
Invacare logo
IVC
Invacare
1.6$9.92-0.1%$341.43 million$927.96 million-8.06
Rockwell Medical logo
RMTI
Rockwell Medical
1.3$1.46-2.7%$136.62 million$61.30 million-3.40
This page was last updated on 1/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.